Alglucosidase alfa
Top View
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- Print Annual Reviews for Fiscal Year 2018
- Specialty Pharmacy Medications
- Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
- Estonian Statistics on Medicines 2017 1/42
- EPAR, INN-Alglucosidase Alfa
- Pompe-Position-Statement.Pdf
- 5.01.576 Drugs for Rare Diseases
- Alglucosidase Alfa (Lumizyme, Myozyme) Reference Number: ERX.SPMN.144 Effective Date: 10/16 Coding Implications Last Review Date: 09/16 Revision Log
- Media Update
- Aralast NP™, Glassia™, Prolastin®-C
- ATB200/AT2221 for Late Onset Pompe Disease in Adults and Adolescents >12 Years –
- Alglucosidase Alfa), for Injection, for Intravenous Use and Hypersensitivity Reactions Have Been Observed in Some Patients During Initial U.S
- Enzyme Related Therapies
- A Baker's Dozen of US FDA E Cacy Approvals Using Real World
- Corporate Medical Policy
- TRANSPARENCY COMMITTEE Opinion 9 January 2013
- Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders